These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16403576)

  • 21. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective.
    Schub N; Günther A; Schrauder A; Claviez A; Ehlert C; Gramatzki M; Repp R
    Bone Marrow Transplant; 2011 Jan; 46(1):143-7. PubMed ID: 20348971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peri-operative alemtuzumab (Campath-1H) and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular assist device support.
    Lick SD; Vaidya S; Kollar AC; Boor PJ; Vertrees RA
    J Heart Lung Transplant; 2008 Sep; 27(9):1036-9. PubMed ID: 18765198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
    Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
    Br J Haematol; 2006 Nov; 135(4):475-85. PubMed ID: 16995884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
    Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
    Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.
    Martin SI; Marty FM; Fiumara K; Treon SP; Gribben JG; Baden LR
    Clin Infect Dis; 2006 Jul; 43(1):16-24. PubMed ID: 16758413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.
    Magliocca JF; Knechtle SJ
    Transpl Int; 2006 Sep; 19(9):705-14. PubMed ID: 16918530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bloodstream infections in pediatric patients.
    Babay HA; Twum-Danso K; Kambal AM; Al-Otaibi FE
    Saudi Med J; 2005 Oct; 26(10):1555-61. PubMed ID: 16228055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004.
    Paul M; Gafter-Gvili A; Leibovici L; Bishara J; Levy I; Yaniv I; Shalit I; Samra Z; Pitlik S; Konigsberger H; Weinberger M
    Isr Med Assoc J; 2007 Jun; 9(6):424-9. PubMed ID: 17642387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Six-month incidence of bloodstream infections in intestinal transplant patients.
    Akhter K; Timpone J; Matsumoto C; Fishbein T; Kaufman S; Kumar P
    Transpl Infect Dis; 2012 Jun; 14(3):242-7. PubMed ID: 22093913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bloodstream infections during the first year after pediatric small bowel transplantation.
    Florescu DF; Qiu F; Langnas AN; Mercer DF; Chambers H; Hill LA; Qaragholi N; Kalil AC
    Pediatr Infect Dis J; 2012 Jul; 31(7):700-4. PubMed ID: 22466325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
    Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
    Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literature.
    Klotz SA; Chasin BS; Powell B; Gaur NK; Lipke PN
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):401-6. PubMed ID: 17888612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China.
    Yuan-Xin L; Ning L; You-Sheng L; Xiao-Dong N; Ming L; Jian W; Jie-Shou L
    Transplant Proc; 2010; 42(1):29-34. PubMed ID: 20172275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Some observations on prope tolerance.
    Calne R; Watson CJ
    Curr Opin Organ Transplant; 2011 Aug; 16(4):353-8. PubMed ID: 21666472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
    Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab.
    Silveira FP; Husain S; Kwak EJ; Linden PK; Marcos A; Shapiro R; Fontes P; Marsh JW; de Vera M; Tom K; Thai N; Tan HP; Basu A; Soltys K; Paterson DL
    Transpl Infect Dis; 2007 Mar; 9(1):22-7. PubMed ID: 17313467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
    Baez Y; Giron F; Niño-Murcia A; Rodríguez J; Salcedo S
    Transplant Proc; 2008 Apr; 40(3):697-9. PubMed ID: 18454990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
    Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
    Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.